The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Effects of Somatostatin on Plasma Glucose and Glucagon Levels in Human Diabetes Mellitus: Pathophysiologic and Therapeutic Implications
Abstract
To evaluate the role of pancreatic alpha-cell dysfunction in human diabetes mellitus, somatostatin, an inhibitor of glucagon secretion, was infused (1 mg over two hours) in 10 insulin-dependent diabetic subjects. Fasting plasma glucagon fell from 150 ± 15 (mean ± S.E.M.) to 77 ± 10 pg per milliliter (p<0.001), and plasma glucose from 260 ± 20 to 191 ± 21 mg per 100 ml (p<0.001). Similar responses occurred in a hypophysectomized diabetic patient, indicating that these effects of somatostatin were independent of suppression of growth hormone secretion. Somatostatin (4 mg subcutaneously) was active transiently. In additional studies, somatostatin infusion combined with insulin completely abolished post-meal hyperglycemia in four diabetic patients and was more effective than insulin alone. These results indicate that excessive glucagon secretion accounts for about 25 per cent of the fasting plasmaglucose levels in such patients. Furthermore, somatostatin may be a useful adjunct to insulin in treating diabetes mellitus. (N Engl J Med 291:544–547, 1974)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Studies of pancreatic alpha cell function in normal and diabetic subjects
Unger, R. H., Aguilar-Parada, E., Müller, W. A., & Eisentraut, A. M. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106297 · Cited by 837
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688
Self-citationGlucagon physiology and pathophysiology
Sherwood, L. M., Parris, E. E., & Unger, R. H. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108192850806 · Cited by 267
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
Peptides in the Brain: The New Endocrinology of the Neuron
Guillemin, R. (1978) · Science · doi:10.1126/science.212832 · Cited by 485
Self-citationThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
FUNCTIONAL SUBDIVISION OF ISLETS OF LANGERHANS AND POSSIBLE ROLE OF D CELLS
Orci, L., & Unger, R. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92078-4 · Cited by 414
Metadata
- Authors
- Gerich, J. E., Lorenzi, M., Schneider, V., Karam, J. H., Rivier, J., Guillemin, R., & Forsham, P. H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1974-09-12
- Volume
- 291
- Issue
- 11
- Pages
- 544-547
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2342294330
- Cited by
- 239
- References
- 3
- FWCI
- 73.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Somatostatin on Plasma Glucose and Glucagon Levels in Human Diabetes Mellitus: Pathophysiologic and Therapeutic Implications. https://app.cochat.ai/papers/10.1056/nejm197409122911102
- The paper
- Gerich, J. E., Lorenzi, M., Schneider, V., Karam, J. H., Rivier, J., Guillemin, R., & Forsham, P. H. (1974). Effects of Somatostatin on Plasma Glucose and Glucagon Levels in Human Diabetes Mellitus: Pathophysiologic and Therapeutic Implications. New England Journal of Medicine. https://doi.org/10.1056/nejm197409122911102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.